Neuroendocrine tumors: current changes in the classification, diagnosis and therapy presented in the draft clinical guidelines of the Ministry of Health of the Russian Federation 2019


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Despite the improvement of diagnostic methods and the developed therapeutic algorithms, the problem of diagnosis and treatment of neuroendocrine tumors is extremely relevant both in the world and in the Russian Federation. This year, updates were made to such sections of clinical guidelines as Pathomorphological and Biochemical Diagnostics, Radionuclide Diagnostics, and Drug Treatment of Neuroendocrine Tumors, the essence of which is reflected in this article.

Texto integral

Acesso é fechado

Sobre autores

V. Gorbunova

N.N. Blokhin National Medical Research Center of Oncology

Email: veragorbounova@mail.ru
MD, Professor 23, Kashirskoye Highway, Moscow 115478, Russian Federation

Bibliografia

  1. Dasari A, Shen C., Haiperin D., et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA. Oncol. 2017;3(10):1335-42. Doi: W.W01/jamaoncol.2017.0589.
  2. Yao J.-C, Hassan M., Phan A., et al. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-72. Doi: 10.1200/ JCO.2007.15.4377.
  3. Ларичева И.В. Подключение и мониторинг регионов РФ для расширения оценки ключевых эпидемиологических параметров распространенности НЭО в РФ. Круглый стол по вопросам диагностики и лечения нейроэндокрин-
  4. Singh S., Granberg D., Wolin E., et al. PatientReported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Global Oncol. 2017;3(1):43-53. Doi: http://dx.doi. org/10.1200/JGO.2015.002980
  5. th Annual ENETS Conference, 6-8 March 2019. URL: https://www.enets.org/about_enets_ coe.html
  6. Нейроэндокринные опухоли. Проект клинических рекомендаций МЗ РФ. 2019.
  7. Liu et al. Impower 133: primary pfs, os and safety in a ph1/3 Study of 1l atezolizumab+carboplatin+ etoposide in Extensive-stage sclc WCLC 2018 Abs PL 02.07. URL: https://wclc2018.iaslc.org/ wp-content/uploads/2018/09/WCLC2018-Abstract-Book_vF-LR-REV-SEPT-25-2018.pdf
  8. NCCN Clin Pract Guidenl Oncol. SCLC v.1 2019. URL: https://www.nccn.org/store/login/login. aspx?ReturnURL=https://www.nccn.org/ professionals/physician_gls/pdf/sclc.pdf

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Bionika Media, 2019

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies